Study wrapper · #730
Therapeutic Effects of MOTS-c in the Valproic Acid-Induced Autism Model in Rats: Role of Tetrahydrobiopterin and Brain-Derived Neurotrophic Factor.
Editor's note
In a valproic-acid rat model of autism, researchers report that MOTS-c reversed several features, impaired sociability, repetitive behaviour, Purkinje-cell loss, and prefrontal oxidative damage, though not anxiety or neocortical damage. Contrary to their hypothesis, MOTS-c did not raise plasma BH4 or BDNF, so the mechanism appears independent of those messengers. This is a single-model preclinical study with partial, mixed effects and an unconfirmed mechanism. These are preclinical findings; human data are needed before any clinical conclusions can be drawn. MOTS-c is generally reported not to cross the blood-brain barrier, which the authors note, making the central effects intriguing but requiring explanation. Weight this as an early, incomplete animal signal, not evidence relevant to people.
Plain-language abstract
Autism spectrum disorder has limited treatment options, and oxidative stress may play a role. Because exercise (hard for many to sustain) can ease symptoms partly through a molecule called AMPK, researchers tested MOTS-c, a mitochondria-derived peptide that also activates AMPK, in a rat model of autism created by prenatal exposure to valproic acid. The exposed rats showed reduced sociability, repetitive behaviours, anxiety, loss of certain brain cells, and oxidative brain damage. MOTS-c reversed several of these, including social problems and some brain-cell damage, but did not help anxiety or one type of cortical damage. Surprisingly, it did not raise the two brain-signalling molecules (BH4 and BDNF) the researchers expected, so it seems to work another way. Since MOTS-c is thought not to easily enter the brain, these central effects are puzzling and need explanation. This was an animal study, so it says nothing definitive about people, and human research would be needed.